Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Objectives: To assess the effect of vitamin D supplementation on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis and determine whether supplementation of more than 800 IU/day, which is the currently recommended dose, is beneficial.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were classified into four groups according to the dosage of vitamin D supplementation, which were as follows: 0, 400, 800, and ≥1,000 IU/day.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis

Study design awaiting verification · Frontiers in Medicine · 2020

Original publication title

Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis

Oh Chan Kwon; Ji Seon Oh; Min-Chan Park; Yong-Gil Kim

Copyright © 2020 Kwon, Oh, Park and Kim.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusion:

In RA patients with osteoporosis receiving bisphosphonates, vitamin D supplementation was associated with a higher increase in BMD. This effect was higher in the vitamin D supplementation dose of ≥1,000 IU/day than in 800 IU/day.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To assess the effect of vitamin D supplementation on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis and determine whether supplementation of more than 800 IU/day, which is the currently recommended dose, is beneficial.

Source: Objectives:

Abstract: What methods does the paper describe?

RA patients with osteoporosis who received bisphosphonate were included. Patients were classified into four groups according to the dose of vitamin D supplementation (0, 400, 800, and ≥1,000 IU/day). Multivariable linear regression models were performed to evaluate the effect of each dose of vitamin D supplementation on 1-year% change of BMD.

Source: Methods:

Abstract: Results

In total, 187 RA patients with osteoporosis were included. In the multivariate model adjusted for potential confounders, patients receiving vitamin D supplementation had a significantly higher increase in 1-year % change in lumbar spine BMD (400 IU/day: β = 2.51 [95% CI: 0.04 to 4.99], 800 IU/day: β = 2.90 [95% CI: 0.47 to 5.33], and ≥1,000 IU/day: β = 6.01 [95% CI: 3.71 to 8.32]) and femoral neck BMD (400 IU/day: β = 3.88 [95% CI: 1.83 to 5.94], 800 IU/day: β =4.30 [95% CI: 2.25 to 6.35], and ≥1,000 IU/day: β = 6.79 [95% CI: 4.87 to 8.71]) than those not receiving the supplementation. Notably, the ≥1,000-IU/day group had a significantly higher increase in 1-year % change in lumbar spine BMD (β = 3.11 [95% CI: 0.86 to 5.37]) and femoral neck BMD (β = 2.50 [95% CI: 0.63 to 4.36]) than the 800-IU/day group.

Source: Results:

Abstract: Conclusion

In RA patients with osteoporosis receiving bisphosphonates, vitamin D supplementation was associated with a higher increase in BMD. This effect was higher in the vitamin D supplementation dose of ≥1,000 IU/day than in 800 IU/day.

Source: Conclusion:
Authors’ abstract

Objectives:

To assess the effect of vitamin D supplementation on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis and determine whether supplementation of more than 800 IU/day, which is the currently recommended dose, is beneficial.

Methods:

RA patients with osteoporosis who received bisphosphonate were included. Patients were classified into four groups according to the dose of vitamin D supplementation (0, 400, 800, and ≥1,000 IU/day). Multivariable linear regression models were performed to evaluate the effect of each dose of vitamin D supplementation on 1-year% change of BMD.

Results:

In total, 187 RA patients with osteoporosis were included. In the multivariate model adjusted for potential confounders, patients receiving vitamin D supplementation had a significantly higher increase in 1-year % change in lumbar spine BMD (400 IU/day: β = 2.51 [95% CI: 0.04 to 4.99], 800 IU/day: β = 2.90 [95% CI: 0.47 to 5.33], and ≥1,000 IU/day: β = 6.01 [95% CI: 3.71 to 8.32]) and femoral neck BMD (400 IU/day: β = 3.88 [95% CI: 1.83 to 5.94], 800 IU/day: β =4.30 [95% CI: 2.25 to 6.35], and ≥1,000 IU/day: β = 6.79 [95% CI: 4.87 to 8.71]) than those not receiving the supplementation. Notably, the ≥1,000-IU/day group had a significantly higher increase in 1-year % change in lumbar spine BMD (β = 3.11 [95% CI: 0.86 to 5.37]) and femoral neck BMD (β = 2.50 [95% CI: 0.63 to 4.36]) than the 800-IU/day group.

Conclusion:

In RA patients with osteoporosis receiving bisphosphonates, vitamin D supplementation was associated with a higher increase in BMD. This effect was higher in the vitamin D supplementation dose of ≥1,000 IU/day than in 800 IU/day.

Publication and source details

Original title: Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis

Oh Chan Kwon; Ji Seon Oh; Min-Chan Park; Yong-Gil Kim

Frontiers in Medicine · 2020

Edited by: Barbara Ruaro, Centro Cardinal Ferrari, Italy

Reviewed by: Mario Salazar-Paramo, University of Guadalajara, Mexico; Xavier Noguès, Université de Bordeaux, France; José Antonio P. Da Silva, University of Coimbra, Portugal

*Correspondence: Min-Chan Park mcpark@yuhs.acYong-Gil Kim bestmd2000@amc.seoul.kr

This article was submitted to Rheumatology, a section of the journal Frontiers in Medicine

Copyright © 2020 Kwon, Oh, Park and Kim.2020Kwon, Oh, Park and Kimhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Yonsei University College of Medicine10.13039/5011000080056-2019-0111National Research Foundation of Korea10.13039/501100003725NRF-2019R1F1A1059736

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:33:28.011941+00:00

DOI: 10.3389/fmed.2020.00443 · PMC7473387